Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 738 • 2018 ACR/ARHP Annual Meeting
Two Clinical Phenotypes of Chinese SLE-PAH Patients
Fangfang Sun¹, Wanlong Wu², Li Guo¹, Zhiwei Chen¹, Xiaodong Wang¹, Ting Li¹ and Shuang Ye¹, ¹Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ²Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), which is the most common underlying disease of CTD associated PAH.…
Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Daniel J. Wallace¹, Richard Furie², Yoshiya Tanaka³, Kenneth C. Kalunian⁴, Marta Mosca⁵, Michelle Petri⁶, Thomas Dorner⁷, Mario H. Cardiel⁸, Ian N. Bruce⁹, Elisa Gomez¹⁰, Amy M. DeLozier¹⁰, Jonathan Janes¹⁰, Matthew D Linnik¹⁰, Stephanie de Bono¹⁰, Maria E. Silk¹⁰ and Robert W. Hoffman¹⁰, ¹Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of California at San Diego School of Medicine, La Jolla, CA, ⁵University of Pisa, Pisa, Italy, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Charité Universitätmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ⁸Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…
Abstract Number: 1671 • 2018 ACR/ARHP Annual Meeting
Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus
Cynthia Aranow¹, Anca Askanase², Molla Huq³, Shereen Oon⁴, Alicia Calderone⁴, Eric Morand⁵ and Mandana Nikpour⁶, ¹Feinstein Institute for Medical Research, Mahasset, NY, ²Columbia University, College of Physicians & Surgeons, New York, NY, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴The University of Melbourne at St. Vincent’s Hospital, Melbourne, Australia, ⁵Monash University, Melbourne, Australia, ⁶The University of Melbourne, Melbourne, Australia, Melbourne, Australia
Background/Purpose: The Physician Global Assessment (PGA) is a frequently-used outcome measure in Systemic Lupus Erythematosus (SLE). The PGA is intended to encapsulate the physician’s judgement…
Abstract Number: 1678 • 2018 ACR/ARHP Annual Meeting
How Consistently Do Publications Define SLE? a Systematic Review
Linjia Jia¹, Ecem Sevim², Medha Barbhaiya² and Michael Lockshin³, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous. ACR and/or SLICC classification criteria provide homogeneous populations for research purposes, but studies differ in selection and…
Abstract Number: 1695 • 2018 ACR/ARHP Annual Meeting
Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients
Rodrigo Aguila Maldonado¹, Dora Pereira², Gisela Pendon³, Alberto Spindler⁴, Cecilia N. Pisoni⁵, Julio Hofman⁶, María Victoria Collado⁷, Judith Sarano⁸, Cesar Graf⁹, Graciela N Gómez¹⁰, Paula Alba¹¹, Claudia Elizabeth Pena¹, Ana Carolina Costi¹², Adrian Salas¹³, Ana Curti¹⁴, Oscar Rillo¹⁵, Silvia Beatriz Papasidero¹⁶, Veronica Bellomio¹⁷, Susana Roverano¹⁸, Marcela Schmid¹⁹, Alberto Allievi²⁰, Sebastián Muñoz²⁰, Walter J. Spindler²¹, Andrea Gonzalez²², Ana María Beron²³, Rosana Quintana²⁴, Agustina Damico²⁵, Andrea Gómez²⁶, Sergio Tolosa²⁷, Enrique Soriano²⁸, Alicia Eimon²⁹, Marta Silvia Espósito⁶, Leila Romina Ferreyra Mufarregue³⁰, Juan Pablo Ruffino³⁰, Verónica Saurit³¹, Edson Hernán Chiganer³⁰, Fabian Risueño³², Flavia Caputo³³, Edson Velozo³⁴, Juan Soldano³⁵, Monica Diaz³⁶ and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology Section, Hospital Dr. Ricardo Gutiérrez, Argentina, Buenos Aires, Argentina, ³H Gutiérrez de La Plata, La Plata, Argentina, ⁴Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ⁵Internal Medicine, CEMIC, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, ⁶Consultorio Privado, Buenos Aires, Argentina, ⁷Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Centro Médico Mitre, Paraná, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹¹Universidad Nacional de Cordoba, Rheumatology Unit Cordoba and Materno Neonatal Hospital, Córdoba, Argentina, ¹²Rheumatology Section, HIGA General San Martin La Plata, La Plata, Argentina, ¹³Rheumatology, HIGA General San Martin, La Plata, Argentina, ¹⁴Htal Lagomaggiori, Mendoza, Argentina, ¹⁵Hospital General de Agudos Dr Ignacio Pirovano, Argentina, Buenos Aires, Argentina, ¹⁶Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ¹⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ¹⁸Hospital José Maria Cullen, Santa Fe, Argentina, ¹⁹Hospital Jose María Cullen, Santa Fe, Argentina, ²⁰SAR, Buenos Aires, Argentina, ²¹Centro Médico Privado de Reumatología, Tucuman, Argentina, ²²Hospital Eva Perón, San Martín, Argentina, ²³Hospital de Clínicas, Buenos Aires, Argentina, ²⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ²⁵Hospital Británico, Buenos Aires, Argentina, ²⁶Hospital Británico de Buenos Aires, CABA, Argentina, ²⁷Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ²⁸Hospital Italiano, Buenos Aires, Argentina, ²⁹CEMIC, Buenos Aires, Argentina, ³⁰Hospital Durand, Buenos Aires, Argentina, ³¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³²Itemédica, Bahia Blanca, Argentina, ³³Hospital Posadas, Buenos Aires, Argentina, ³⁴Sanatorio Adventista del Plata, Entre Ríos, Ecuador, ³⁵Hospital Provincial, Rosario, Argentina, ³⁶SAR, Bariloche, Argentina
Background/Purpose: Approximately 20% of patients with Systemic Lupus Erythematosus (SLE) begin their illness in childhood or adolescence. These patients are described with a phenotype of…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 2677 • 2018 ACR/ARHP Annual Meeting
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Edward R. Hammond¹, Dora H. Lin², Irene B. Murimi², Henk Nab³, Hong Kan², Oluwadamilola Onasanya², Jonothan Tierce², Xia Wang¹, Barnabas Desta¹ and G. Caleb Alexander², ¹AstraZeneca, Gaithersburg, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE-related organ damage is associated with increased morbidity. The comorbidity burden of SLE can involve various organ systems and may include pain, fatigue, difficulty…
Abstract Number: 2627 • 2017 ACR/ARHP Annual Meeting
Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort
Justin Levinson¹, Maushmi Savjani¹, Diane Zisa² and Ellen M. Ginzler³, ¹Internal Medicine, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ³Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY
Background/Purpose: SLE patients frequently utilize the Emergency Department (ED), impacting the cost of care and quality of life. We performed a retrospective analysis of ED…
Abstract Number: 2629 • 2017 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects
Barbara Ruaro¹, Alberto Sulli¹, Sabrina Paolino², Carmen Pizzorni³, Veronica Tomatis¹, Massimo Patanè¹ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ²University of Genova, IRCCS San Martino, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, Genova, Italy
Background/Purpose: A clinical feature of patients with primary Raynaud's phenomenon (PRP) is the presence of low skin blood perfusion (BP) at the level of hands…
Abstract Number: 2631 • 2017 ACR/ARHP Annual Meeting
Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE
Pinar Ozge Avar Aydin¹, Michael J. Holland², Simone Appenzeller³, Stacy P. Ardoin⁴, Tadej Avcin⁵, Michael W. Beresford⁶, Brian M. Feldman⁷, Francisco Flores⁸, Marisa S. Klein-Gitelman⁹, Beatrice Goilav¹⁰, Raju Khubchandani¹¹, Deborah M. Levy¹², Angelo Ravelli¹³, Nicolino Ruperto¹⁴, Clovis A Silva¹⁵, Scott E. Wenderfer¹⁶, Jun Ying¹⁷ and Hermine I. Brunner¹, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ⁴Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ⁶On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, ⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, ¹²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹³University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴Istituto Giannina Gaslini, Genoa, Italy, ¹⁵Rheumatology Unit, Instituto da Criança, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ¹⁶Nephrology, Baylor College of Medicine, Texas Children's Hospital, houston, TX, ¹⁷Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease that is characterized by episodes of flares followed by improvement in response to therapy.…
Abstract Number: 687 • 2017 ACR/ARHP Annual Meeting
Homocysteine Levels Are Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Patients (SLE)
Paola Zeña-Huancas¹, Manuel Ugarte-Gil^2,3, Rocío Gamboa-Cárdenas¹, Francisco Zevallos¹, Mariela Medina¹, Victor Pimentel-Quiroz², Claudia Elera-Fitzcarrald¹, Omar Sarmiento-Velasquez¹, Cristina Reategui-Sokolova¹, Mariano Cucho-Venegas¹, José Alfaro-Lozano¹, Zoila Rodriguez-Bellido^1,4, Cesar A. Pastor-Asurza^1,4, Graciela S. Alarcón⁵ and Risto Perich-Campos^4,6, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Peru, GLADEL, Lima, Peru, ³Universidad Cientifica del Sur, Lima, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology, Hospital Guillermo Almenara Irigoyen, Lima, Peru
Background/Purpose: Homocysteine level is a predictor of the occurrence of cardiovascular diseases, however, its role as a predictor of damage in SLE has not been…
Abstract Number: 1646 • 2017 ACR/ARHP Annual Meeting
Cardiovascular disease in Systemic Lupus Erythematosus. The road to hell is paved with good intentions
Sophie Mavrogeni¹ and Loukia Koutsogeorgopoulou², ¹CMR Department, Onassis Cardiac Surgery Center, Athens, Greece, ²Department of Pathophysiology, Rheumatology Unit, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Accurate diagnosis of cardiovascular involvement in systemic lupus erythematosus (SLE) remains challenging, because echocardiography (echo), the cornerstone tool used, has serious limitations. We hypothesized…
Abstract Number: 1654 • 2017 ACR/ARHP Annual Meeting
Predictive Factors According to Type of Infection in Systemic Lupus Erythematosus Patients: Data from a Multi-Ethnic, Multi-National, Latin-American Cohort
Victor R. Pimentel-Quiroz¹, Manuel Ugarte-Gil¹, Guillermo J. Pons-Estel², Daniel Wojdyla³, Mario Cardiel⁴, Virginia Pascual-Ramos⁵, Ignacio Garcia-De La Torre⁶, Leonor Barile⁷, Mary Carmen Amigo⁸, Luis H. Silveira⁹, Maria Josefina Sauza del Pozo¹⁰, Marlene Guibert-Toledano¹¹, Gil A. Reyes¹², Antonio Iglesias-Gamarra¹³, Gloria Vasquez¹⁴, José Fernando Molina¹⁵, Jose A Gómez-Puerta¹⁶, Luis Alonso Gonzalez¹⁷, Rosa Chacón-Díaz¹⁸, Maria H Esteva Spinetti¹⁹, Isaac Abadi¹⁹, Eduardo M. Acevedo-Vásquez²⁰, Jose Alfaro-Lozano²¹, Ines Segami²², Loreto Massardo²³, Oscar Neira²³, Emilia Sato²⁴, Eloisa Bonfa²⁵, Eduardo Borba²⁶, Graciela S. Alarcón²⁷ and Bernardo Pons-Estel²⁸, ¹Peru, GLADEL, Lima, Peru, ²GLADEL, Rosario, Argentina, ³GLADEL consultant, Rosario, Argentina, ⁴Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico, ⁶Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ⁷GLADEL, Mexico, Mexico, ⁸Centro Medico ABC, Mexico, Mexico, ⁹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ¹⁰Servicio de Reumatología, Instituto Mexicano de Seguro Social, Hospital de Especialidades Nº 25, Monterrey, Mexico, ¹¹Centro de Investigaciones Médico Quirúrgicas, Habana, Centro de Investigaciones Médico Quirúrgicas, Habana, La Habana, Cuba, ¹²GLADEL, Havana, Cuba, ¹³Clinical Development, Nordic Bioscience, Herlev, Denmark, ¹⁴GLADEL, Colombia, Antioquia, Colombia, ¹⁵GLADEL, Colombia, Antoquia, Colombia, ¹⁶Grupo de Reumatología, Universidad de Antioquia, Medellín, Colombia, ¹⁷Medicarte IPS, Medellín, Colombia, ¹⁸Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ¹⁹GLADEL, Caracas, Venezuela (Bolivarian Republic of), ²⁰Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ²¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²²GLADEL, Peru, Lima, Peru, ²³GLADEL, Santiago, Chile, ²⁴Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²⁵Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁶Faculdade de Medicina, Hospital das Clínicas. Universidade de São Paulo, São Paulo, Brazil, ²⁷University of Alabama at Birmingham, Birmingham, AL, ²⁸GLADEL, Rosario, Santa Fe, Argentina
Background/Purpose: While infections are a one of the main causes of mortality in systemic lupus erythematosus (SLE), the type of infections and the factors predisposing…
Abstract Number: 2610 • 2017 ACR/ARHP Annual Meeting
Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus
Niti Goel¹, Stephen Wax², Amy Kao², Russell Reeve³ and Marsha Mackey⁴, ¹QuintilesIMS, Duke University School of Medicine, Durham, NC, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA), Billerica, MA, ³QuintilesIMS, Durham, NC, ⁴QuintilesIMS, Rockville, MD
Background/Purpose: Tuberculosis (TB) has been reported to occur at a higher rate in SLE patients than in the general population. As a result, most clinical…
Abstract Number: 2619 • 2017 ACR/ARHP Annual Meeting
Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
Ana Lois-Iglesias¹, Francisco J. de Toro², Antonio Zea³, María Galindo⁴, Esther Uriarte⁵, Iñigo Rúa-Figueroa⁶ and JM Pego-Reigosa⁷, ¹Rheumatology, University Hospital A Coruña, A Coruña, Spain, ²Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ³Hospital Ramón y Cajal. Madrid, Madrid, Spain, ⁴Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁵Reumatología, Hospital de Donosti, Donosti, Spain, ⁶Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁷Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune systemic rheumatic disease that, in our area, presents hematologic manifestations in approximately 70% of cases1. Some of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].